A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure
Status:
Completed
Trial end date:
2015-07-31
Target enrollment:
Participant gender:
Summary
A randomized, double-blinded, placebo-controlled study of continuous 6-hour IV infusions of
CXL-1427 in hospitalized patients with systolic heart failure.